Melanoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Melanoma Market Outlook

Thelansis’s “Melanoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Melanoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Melanoma Overview

Melanoma originates from melanocytes found in pigmented tissues, including the skin, eyes, and intestines. Approximately 90% of melanoma cases are initially diagnosed as primary tumors, showing no signs of metastasis. However, melanoma tends to spread to the brain when it becomes malignant. The major oncogenic mutations associated with melanoma involve genes like BRAF, NRAS, c-KIT, PTEN, and GNAQ/GNA11. Among these, BRAF mutations are the most extensively studied, with a prevalence ranging from 50% to 60% in primary melanoma cases. A small percentage, around 5% to 12% of melanoma patients, have a family history of cutaneous malignant melanoma (CMM) in their first-degree relatives. Over 75 somatic mutations in the BRAF gene have been identified in melanoma, all of which lead to the constitutive activation of BRAF. These mutations are found in the activating segment within exon 15 or the glycine-rich loop (P-loop) in exon 11 of the BRAF protein's kinase domain. In BRAF mutant melanoma cases, V600E mutations account for 74% to 90%, while V600K mutations make up 16% to 29% of the cases. The frequency of BRAF mutations in primary melanomas varies from 50% to 60%.

• In the United States, the estimated incidence of melanoma is approximately 25.3 cases per 100,000 people.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: